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a  b  s  t  r  a  c  t
The  involvement  of  A to  I  RNA  editing  in  antiviral  responses  was  ﬁrst  indicated  by  the  observation  of
genomic hyper-mutation for  several  RNA viruses  in the course  of  persistent  infections.  However,  in only
a few  cases  an  antiviral  role  was ever  demonstrated  and  surprisingly,  it turns  out that  ADARs  – the  RNA
editing  enzymes  – may  have  a  prominent  pro-viral  role  through  the  modulation/down-regulation  of  the
interferon  response.  A key  role  in  this  regulatory  function  of  RNA  editing  is  played  by ADAR1,  an  interferon
inducible  RNA  editing  enzyme.  A distinguishing  feature  of  ADAR1,  when  compared  with  other  ADARs,
is  the  presence  of  a  Z-DNA  binding  domain,  Zalpha.  Since  the  initial  discovery  of the  speciﬁc  and  high
afﬁnity  binding  of  Zalpha  to CpG  repeats  in  a left-handed  helical  conformation,  other  proteins, all related
to  the  interferon  response  pathway,  were  shown  to have  similar  domains  throughout  the  vertebrate
lineage.  What  is  the  biological  function  of this  domain  family  remains  unclear  but  a signiﬁcant  body  of
work provides  pieces  of  a puzzle  that points  to an  important  role  of  Zalpha  domains  in  the  recognition  of
foreign  nucleic  acids  in the cytoplasm  by  the  innate  immune  system.  Here  we will  provide  an  overview
of  our  knowledge  on  ADAR1  function  in  interferon  response  with  emphasis  on Zalpha  domains.
© 2011 Published by Elsevier Ltd.
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1. Introduction32
In biology what you see is not always what you get. The dis-33
covery of RNA editing in Xenopus eggs in 1988 [1] and extensive34
research since have challenged a deeply rooted belief that the35
Abbreviations: ADAR, adenosine deaminase acting on RNA; A to I, adenosine to
inosine; PKR, protein kinase RNA depended; DAI, DNA depended Activator of IRFs;
IFN,  interferon; CNS, central nervous system; eIF2a, eukaryotic initiation factor 2a;
HIV, human immunodeﬁciency virus.
∗ Tel.: +351 21 4464648; fax: +351 21 4407970.
E-mail address: alekos@igc.gulbenkian.pt
sequence of transcribed nuclear RNA is a faithful copy of the 36
genomic sequence. This RNA modiﬁcation was  found to be present 37
in all metazoans and was  termed A to I RNA editing because it 38
consists in the hydrolytic deamination of adenosines (A) toino- 39
sine (I) within RNAs. Inosine base-pairs with cytosine instead of 40
thymine and so for any biological process that involves recognition 41
of the RNA sequence through base pairing, inosine is an equivalent 42
of guanosine. As a consequence, A to I editing is able to recode 43
aminoacid sequences [2],  to alter splice sites [3],  create miRNA 44
binding sites and change the speciﬁcity of miRNAs themselves [4].  45
Responsible enzymes for this RNA modiﬁcation are adenosine 46
deaminases called ADARs that show limited target sequence 47
1084-9521/$ – see front matter ©  2011 Published by Elsevier Ltd.
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speciﬁcity [5]. Instead, their speciﬁcity is determined primarily48
by the secondary structure of the RNA substrate [6].  While ADARs49
modify a perfect RNA duplex in a promiscuous manner leading50
up to 50% of modiﬁed adenosines, the modiﬁcation can be highly51
speciﬁc towards complex RNA structures containing bulges and52
internal loops [6].53
The discovery that this RNA modiﬁcation leads to functionally54
critical aminoacid changes in vertebrate neurotransmitter recep-55
tors like the GluR-2, GluR-5 and -6 subunits of AMPA receptors,56
the Serotonin-2C (reviewed in [2,7]) and the -amino butyric acid57
(GABA) receptors [8] as well as in invertebrate chloride channel58
subunits [9], nicotinic acetylcholine receptor (nAChR) subunits [10]59
and several other proteins involved in fast synaptic transmission60
[11], led to the notion that the primary role of A to I RNA edit-61
ing is to provide the much needed diversity in the proteome of62
the animal central nervous system (CNS). This notion however left63
unexplained the observed abundance of RNA editing activity out-64
side of the CNS.65
Indeed, in recent years transcriptome analysis has shown that66
ADARs, the A to I RNA editing enzymes, are responsible for exten-67
sive modiﬁcation of 3′UTR and intronic sequences of thousands of68
human genes [12–15] targeting secondary structures often created69
by pairs of inverted repetitive elements. These ﬁndings indicate70
that any extensive and stable pre-mRNA stem-loop structure is71
accessible to ADARs and a potential target for RNA editing and72
have led to a wide rethinking regarding the primary role of this73
post-transcriptional modiﬁcation.74
Double stranded RNA in the cytoplasm is known to repre-75
sent a danger signal indicating viral infection and several antiviral76
pathways are triggered by dsRNA including the RNA interference77
pathway in invertebrates [16] and the interferon response in ver-78
tebrate cells [17]. Through the introduction of mismatches in RNA79
duplexes, A to I RNA editing can reduce their double stranded80
nature and mark such duplexes with Inosine. Could nuclear A to81
I RNA editing prevent the exposure of cellular mRNAs contain-82
ing  dsRNA structures to such antiviral pathways? Is RNA editing83
in the cytoplasm responsible for limiting the duration and/or the84
intensity of active antiviral responses? While evidence linking A85
to I RNA editing to antiviral responses dates back to its discovery,86
in the recent years several lines of research converge on an unex-87
pected role for the editing machinery in the modulation of cellular88
responses to foreign nucleic acids.89
2. Links between A to I RNA editing and immunity90
The ﬁrst evidence for a role of A to I RNA editing in immu-91
nity came with the discovery of modiﬁcations in several viral RNA92
genomes and viral transcripts. These modiﬁcations were shown93
to take the form either of genomic hyper-editing in the course94
of persistent viral infections or more speciﬁc RNA editing events95
in structured viral mRNAs. A second and independent line of evi-96
dence for a role of RNA editing in innate immunity comes from97
work implicating the interferon inducible ADAR1 editing enzyme98
in the regulation of the antiviral interferon response.99
2.1. Modiﬁcation of viral nucleic acids100
Viral nucleic acids have been among the ﬁrst known sub-101
strates of ADARs: the discovery of hyper-mutated RNA genomes102
of measles virus [18] and other members of the paramyxoviridae103
family was followed by similar observations for Vesicular Stomati-104
tis Virus and mRNAs of the mouse polyoma DNA-virus reviewed in105
[19–21].  More recently similar hypermutation was  observed in the106
invertebrate sigma RNA-virus [22] involving the ADAR enzyme of107
drosophilids. These ﬁndings were taken to suggest an antiviral role108
of ADAR mediated RNA editing, mechanistically based on scram- 109
bling the information content of viral nucleic acids, not unlike the 110
role of the APOBEC3 family of cytidine deaminases in retroviral 111
restriction. However, in only few cases an antiviral role of ADARs 112
has been demonstrated and even in these cases it still remains 113
unclear if this is a direct result of hyper-editing of viral nucleic acids 114
or the result of the inﬂuence of ADARs on elements of the innate 115
immune system. Indeed, knockdown of ADAR1 in an ADAR2−/− 116
background in cell culture is shown to alter the cytopathic effects 117
of polyoma virus infection [23] in a manner independent of the 118
modiﬁcation of viral RNA. 119
Speciﬁc editing within a well-deﬁned sequence and structure 120
context of viral nucleic acids was  ﬁrst demonstrated for Hepati- 121
tis D virus (HDV) [24]. Surprisingly, HDV was shown to make use 122
of the cellular RNA editing machinery for its own needs: a stop 123
codon in Hepatitis delta antigen is being changed to a tryptophan 124
codon by RNA editing allowing the switch from the replication stage 125
to the packaging stage, thus enabling, viral proliferation. Inter- 126
estingly, HIV replication is also shown to be enhanced in cells 127
over-expressing ADAR1, and HIV transcripts of Rev and Tat cod- 128
ing sequences as well as the TAR RNA are shown to be edited by 129
ADAR1. However, it remains unclear whether the increased repli- 130
cation is editing depended [25–27].  Speciﬁc RNA editing has also 131
been found in transcripts of the Kaposi sarcoma associated virus 132
(KSHV) [28,29], where again RNA editing appears to be adapted by 133
the virus as the levels of editing correlate with the replicative state 134
of the virus [29]. 135
In summary, for both the hyper-editing and the more speciﬁc 136
editing events observed in viral nucleic acids there is no clear evi- 137
dence that these base modiﬁcations overall represent an antiviral 138
action of ADARs. On the contrary, for viruses like Hepatitis D,  RNA 139
editing represents a valuable cellular contribution. 140
2.2. ADAR1 as a regulator of antiviral responses 141
In vertebrate species we  ﬁnd two  genes encoding for active 142
dsRNA dependent adenosine deaminases: ADAR1 and ADAR2. 143
ADAR1 was the ﬁrst to be discovered and expression of an 144
N-terminally extended form of the protein was  shown to be up- 145
regulated during viral infection. Indeed, ADAR1 comes in two 146
isoforms: a short, constitutively expressed and nuclear form (P110) 147
and a longer, mainly cytoplasmic form (P150) which is transcribed 148
from a different promoter responsive to type I and type II inter- 149
ferons [30] (Fig. 1A). The homozygous knockout of the ADAR1 150
gene in mice is embryonic lethal and its phenotypic characteriza- 151
tion shows that its lethality is associated with extensive apoptosis 152
in the hematopoietic tissue [31,32]. Further characterization of 153
hematopoietic stem cells derived from an inducible ADAR1 gene 154
knockout in mice shows a global upregulation of interferon respon- 155
sive genes during embryonic development [33] pointing to a role of 156
ADAR1 as a suppressor of interferon signaling. Selective knockout 157
of the interferon controlled isoform P150 [34] suggests that this iso- 158
form is responsible for the observed embryonic lethality, although 159
there is an ongoing debate on this matter. 160
The mechanism through which ADAR1 exerts control over 161
innate immune responses has not been yet clariﬁed. Clues however, 162
have been obtained in studies showing that ADAR1 can antago- 163
nize protein kinase R (PKR) [35,36],  a key protein of interferon 164
response that mediates shutdown of cellular translation through 165
the phosphorylation of eukaryotic initiation factor eIF2a during 166
infection. PKR is activated by dsRNA and ADAR1 can inhibit its acti- 167
vation either through the sequestration of dsRNA or by rendering 168
such dsRNA unrecognizable by PKR through modiﬁcation. Indeed, 169
ectopic ADAR1 expression results in a general increase in protein 170
translation through the inhibition of PKR [37,38] and possibly of 171
other dsRNA activated effector proteins of the interferon response 172
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Fig. 1. Domain organization of proteins with Zalpha motifs (A). ADAR1 isoforms P150 and P110 are indicated. RBD stands for dsRNA binding domain. The domain organization
of  PKR is shown for comparison with PKZ. Conserved interactions between Zalpha domains and Z-DNA (B). Ty177, Asn173 and Trp195 positioned to recognize the characteristic
Z-DNA phosphate backbone and a guanosine in Syn conformation.
such as the 2′-5′-oligoadenylate synthetase (OAS). A key ques-173
tion that arises is whether and to what extend cellular transcripts174
containing dsRNA can erroneously activate dsRNA dependent path-175
ways and whether the observed extensive editing in such cellular176
RNA duplexes can have a preventive role. Experiments aiming to177
answer this question show that a single transcript containing a178
long dsRNA hairpin activates interferon response only at abnor-179
mally high expression levels [39]. However, given that there are180
possibly thousands of genes producing transcripts with embedded181
dsRNA structures, the activation of interferon response by cellular182
RNAs seems possible.183
Another dsRNA dependent pathway that acts as an antiviral184
response in invertebrates but also present in vertebrates, is RNA185
interference (RNAi). An interaction between ADARs and the RNAi186
pathway was ﬁrst suggested in experiments in Caenorhabditis ele-187
gans showing that the ADAR knockout phenotype can be rescued188
by the ablation of components of the RNAi machinery [40]. More189
recent work also in C. elegans provides support for a speciﬁc role190
of ADARs to protect an extensive population of dsRNA in cellular191
transcripts from RNAi [41]. RNAi of dsRNA in mammalian cellular192
transcripts has been recently demonstrated in oocytes [39] as well193
as the ability of ADARs, and in particular of cytoplasmic ADAR1194
P150 to bind siRNA and limit the efﬁcacy of the RNAi pathway [42].195
Thus, in vertebrates ADAR1 is shown to antagonize both RNA196
interference and the interferon response. In doing so, ADAR1 may197
limit dsRNA dependent responses not only against cellular RNA but198
also against viral RNA. Indeed, in a survey for the effects of 380199
IFN-regulated genes on viral proliferation, is shown to signiﬁcantly200
enhance the replication rates of all tested viruses [43] supporting a201
pan-viral mechanism of enhancement.202
An attractive model based on the available data ascribes a dual203
function of ADAR1: in the nucleus, it keeps under control the204
amount of cellular dsRNA that can reach dsRNA sensors in the cyto-205
plasm while upon prolonged activation of the interferon pathway206
the P150 isoform migrates to the cytoplasm where it down-207
regulates antiviral responses by limiting the available dsRNA. This208
model establishes ADAR1 as a central node within a feedback mech- 209
anism that limits runaway antiviral responses and their cytopathic 210
effects. 211
What are the molecular details of ADAR1 action in the cytoplasm 212
and what are its interactions with the cytoplasmic nucleic acids 213
sensors? The answer to these questions must largely be found at the 214
296 aminoacids (in humans) long extension at the N-terminus of 215
the interferon inducible P150 isoform. The unique recognizable and 216
conserved feature of this segment of ADAR1 is a DNA/RNA binding 217
domain of so far unknown biological function, the Zalpha. 218
3. The ADAR1 Zalpha domain 219
The N-terminal domain of ADAR1 was  the surprising yield of an 220
in vitro screen for Z-DNA binding domains in blood nuclear extracts 221
[44] and from this discovery derives its name: Zalpha. It was  shown 222
that this 78aa domain of ADAR1 binds with high afﬁnity [45] to CpG 223
repeats and that the bound dsDNA forms a left-handed Z-DNA helix, 224
an alternative DNA conformation originally described more than 30 225
years ago [46]. While in vitro formation of Z-DNA requires high salt 226
concentrations, the Zalpha domain is shown to stabilize this con- 227
formation on CpG repeats under physiological salt concentrations. 228
This makes Zalpha the ﬁrst known speciﬁc Z-DNA binding protein 229
domain. 230
3.1. The ADAR1 Zalpha domain structure and its nucleic acids 231
complexes 232
The crystal structure of the ADAR1 Zalpha domain with a 233
T(CG)3dsDNA complex showed that it belongs to the larger fam- 234
ily of winged-Helix-Turn-Helix domains (wHTH), a common DNA 235
binding motif used in this case in a unique conﬁguration [47]. A 236
key role in the recognition of the Z-DNA backbone is played by a 237
triplet of residues: Tyr177, Asn173 and Trp195 (all aminoacid ref- 238
erences are based on human ADAR1-Zalpha numbering), which are 239
all highly conserved among Zalpha domains (Fig. 1B). Tyr177 forms 240
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a -bond with the guanosine in the Syn conformation character-241
istic for Z-DNA, the only direct base contact made by the protein242
and which contributes to the discrimination between the B-DNA243
and Z-DNA conformations. Mutation of any residue in this triplet244
eliminates DNA binding [48]. The remaining protein/DNA contacts245
are with the characteristically shaped Z-DNA phosphate backbone,246
allowing further discrimination of the two DNA-conformers. Inter-247
estingly, two Zalpha domains interact with the DNA duplex without248
forming a physical dimer suggesting a cooperative mode of DNA-249
binding, a feature that is so far seen in all structures of Zalpha250
domains.251
Formation of Z-DNA requires a dinucleotide repeated unit of252
alternating purine/pyrimidine bases suggesting that Zalpha could253
interact with CA/TG repeats in addition to CG. Such repeats how-254
ever show lower propensity of Z-DNA formation and the co-crystal255
structure of Zalpha with these type of sequences had to wait256
until recently [49]. How can Zalpha bind CpG repeats in the con-257
text of a larger DNA segment that cannot be entirely in the left258
handed conformation? The answer to this question came with259
the crystal structure of a Zalpha domain bound to a B–Z junction260
formed at the boundaries of the left handed helix [50] demonstrat-261
ing that such junctions are formed by the extrusion of a single262
base pair at the junction site. Similarly, Z–Z junctions are formed263
when Zalpha binds to imperfect CpG repeats with disruptions of264
the dinucleotide repeat [51]. These crystal structures document265
the molecular details on how Zalpha domains are able to bind Z-266
DNA forming segments within natural DNA molecules of variable267
sequence.268
CpG repeats in dsRNA also adopt a left-handed helical confor-269
mation [52] known as Z-RNA and consequently, this raises the270
possibility that the in vivo target of Zalpha domains could be dsRNA.271
Indeed, CD-spectroscopy conﬁrmed the interaction of Zalpha with272
RNA [53] and the crystal structure of ADAR1 Zalpha with an RNA273
(CG)3 oligonucleotide revealed a Z-RNA structure [54] with signif-274
icant similarities to Z-DNA, making Zalpha one of the rare if not275
unique domains capable to bind dsDNA and dsRNA of the same276
sequence.277
This extensive structural analysis of the recombinant ADAR1278
Zalpha domain demonstrated a consistent behavior and conserved279
interactions of the domain with CpG sequences in a variable nucleic280
acids context.281
3.2.  Interferon response related proteins with Zalpha domains282
Sequence based identiﬁcation of Zalpha domains in other pro-283
teins led to the delineation of the Zalpha domain family (SMART ID:284
SM00550), a subfamily of the winged-Helix-Turn-Helix domains.285
Interestingly, all proteins sharing this motif were found to be286
involved in the interferon response pathway, and particularly com-287
ponents of this antiviral pathway that relate to the intracellular288
recognition of foreign nucleic acids. Two Zalpha domains are found289
in DNA-dependent activator of IFN-regulatory factors (DAI), a cyto-290
plasmic receptor for foreign nucleic acids and activator of the291
production of type I interferons, in Z-DNA dependent protein kinase292
(PKZ), a ﬁsh ortholog of the mammalian PKR, and the pox-viral293
inhibitor of interferon response E3L (Fig. 1A).294
Intriguingly, isolated Zalpha domains from each of these pro-295
teins were not only shown to share high afﬁnity for CpG repeats296
but also a highly conserved mode of interaction with Z-DNA as297
demonstrated by the crystal and NMR  structures of both DAI Zalpha298
domains [55–57],  of Yatapoxvirus E3L [58] and biochemical data299
from the Zalpha domain of PKZ [59]. Such results point to a com-300
mon  function of Zalpha domains and a functional interconnection301
of the proteins that contain them.302
DAI (also known as DLM-1 and ZBP-1) was shown to act as303
a sensor for dsDNA in the cytoplasm activated by TpA and to a304
lesser extent by CpG repeats [60]. A third DNA binding domain (D3) 305
was shown to be primarily responsible for the recognition of TpA 306
repeats and its two  Zalpha domains expectedly play no role in its 307
ability to bind B-form DNA, nevertheless they appear to be required 308
for the activation of the signaling pathway through the interferon 309
regulatory factor 3 (IRF3) [61]. The function of DAI seems to be 310
specialized, playing roles in speciﬁc cell types and for viral infec- 311
tions by cytomegalovirus [62] and Herpes simplex virus [63] but 312
not for example by intracellular bacteria as Legionella pneumophila 313
[64]. 314
PKZ is another nucleic acids sensor with two N-terminal Zal- 315
pha domains. This protein was found so far only in ﬁsh species like 316
zebraﬁsh, Atlantic salmon and goldﬁsh and is an ortholog of the 317
dsRNA dependent protein kinase PKR. PKZ shows a conserved and 318
functional kinase domain but the dsRNA binding domains found 319
in PKR are replaced by Zalpha domains [59]. This kinase appears 320
to maintain the ability to phosphorylate eIF2a like PKR [65] and to 321
block cellular translation. Unlike PKR however, its activity depends 322
on the presence of CpG dsDNA and not poly I:C dsRNA [65]. While 323
both DAI and PKZ appear responsive to CpG DNA the ability of CpG 324
dsRNA to activate these proteins has not been tested, leaving open 325
the possibility that these sensor proteins may  respond to both DNA 326
and RNA. 327
Given the role of Zalpha domains in antiviral responses, it should 328
not come as a surprise that a Zalpha domain is found in E3L, a viral 329
inhibitor of interferon response. E3L is a small two-domain protein 330
found in all poxviruses whose C-terminal dsRNA binding domain 331
blocks PKR activation and is required for viral proliferation. Its N- 332
terminal Zalpha domain appears dispensable for viral replication in 333
cell culture but crucial for pathogenicity in mice [66]. Interestingly, 334
it is shown that replacement of the E3L Zalpha domain with that 335
of ADAR1 or DAI fully supports viral pathogenicity, suggesting that 336
Zalpha domains are functionally interchangeable [66]. TheE3L Zal- 337
pha domain could function through competition for nucleic acids 338
with DAI similar to the mechanism proposed for the inhibition of 339
PKR by its C-terminal dsRNA binding domain. Indeed micro-array 340
analysis shows that the Zalpha domain of E3L blocks a distinct part 341
of the interferon signaling cascade [67] which overlaps with the 342
IRF3-TANK-binding kinase 1 (TBK1) signaling pathway shown to 343
be activated by DAI [60]. 344
3.3. The  non-conforming Zbeta 345
The uniform behavior of Zalpha domains has a single exception: 346
A domain homologous to Zalpha is also present in the constitu- 347
tively expressed isoform of ADAR1. It was named Zbeta reﬂecting 348
its position within ADAR1. This domain in isolation did not demon- 349
strate any afﬁnity for CpG repeats and in mammalian ADAR1 Zbeta 350
domains, the critical aminoacids corresponding to Zalpha Tyr177 351
and Asn173 are mutated. The crystal structure of Zbeta [68] con- 352
ﬁrmed that this domain shares the same architecture with the 353
Zalpha domain but it also shows that Zbeta cannot form inter- 354
actions with DNA equivalent to Zalpha. It is unfortunate that in 355
proteins that contain more than one Zalpha domain (DAI, PKZ) 356
the term Zbeta has been historically used to describe the second 357
domain although the mammalian ADAR1 Zbeta appears to have 358
unique properties not shared by any other member of the family. 359
Indeed, unlike the ADAR1 Zbeta domain the second Zalpha domain 360
of DAI does interact with CpG repeats as it is described in the struc- 361
tures of its complexes with DNA [56,57]. 362
4. In search for the Zalpha domain target and its biological 363
function 364
Despite the very extensive and successful work characterizing 365
the nucleic acids binding properties of Zalpha domains, the in vivo 366
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target(s) of these domains remain elusive. This is partly due to367
the dynamic and transient nature of Z-DNA formation and partly368
because the involvement of these domains in innate immunity sug-369
gests that their nucleic acids target may  only be present during370
speciﬁc host–pathogen interactions. The information available so371
far comes from in vivo cross linking experiments and the effects372
of mutations of the Zalpha domains on the localization of the pro-373
tein.374
4.1.  Nucleic acids bound by Zalpha in vivo375
Pull-down experiments of genomic DNA segments probed for376
Zalpha binding reveal an enrichment in centromeric repeats [69]377
and probably reﬂect regions of Z-DNA formation rather than a func-378
tional association between the mostly cytoplasmic proteins and379
centromers.380
Similar experiments where Zalpha is cross-linked in vivo to381
cellular RNA identiﬁed speciﬁc regions of ribosomal RNA of382
both bacterial and eukaryotic ribosomes [70] associated with the383
domain. Zalpha mediated binding of ADAR1 to the ribosome is384
shown to inhibit translation and the authors propose that the trans-385
lation of ADAR1-bound mRNAs may  be speciﬁcally inhibited this386
way. Such an interference with the translation machinery would387
be in agreement with the ﬁnding that the Zalpha domain of DAI388
is responsible for an association of DAI with stress granules that389
contain stalled translation preinitiation complexes [71]. How such390
action could be reconciled with a proviral role of ADAR1 and the391
general upregulation of translation through the modulation of PKR392
activity remains to be seen.393
The accumulation of negative supercoiling introduced by RNA394
polymerases during transcription plays a key role in the sta-395
bilization of Z-DNA in vivo [72]. In recent years it has been396
shown that detection of certain types of dsDNA in the cytoplasm397
proceeds through its transcription by RNA polymerase III and sub-398
sequent recognition of the resulting 5′-triphosphate-RNA by the399
RIG-I helicase [73]. It is conceivable that Pol III transcription can400
be the source of negative supercoiling that gives rise to Z-DNA401
formation and the site of attachment for Zalpha-containing pro-402
teins. Although E3L is shown to inhibit RIG-I mediated activation403
of interferons against poly-AT DNA, this activity appears to be404
independent from its N-terminal Zalpha domain [74]. The study405
of other types of DNA activator sequences maybe necessary to406
reveal an involvement of Zalpha domains on the Pol III path-407
way.408
5. Concluding remarks409
The universal chemical and structural nature of nucleic acids410
presents a great challenge for cells that have to distinguish between411
self and non-self. CpG sequences and their unique structural fea-412
tures appear to have a central role in this distinction both for Toll413
mediated recognition and for cytoplasmic receptors where Zalpha414
domains may  have a central role. Deregulation of this recognition415
and of the RNA editing process not only can affect the progress416
of pathogen-induced disease but may  also have a crucial role in417
autoimmune diseases and cancer.418
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